BAT-8006 is under clinical development by Bio-Thera Solutions and currently in Phase I for Breast Cancer. According to GlobalData, Phase I drugs for Breast Cancer have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how BAT-8006’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BAT-8006 is under development for the treatment of solid tumors, ovarian cancer, endometrial cancer, NSCLC, cervical cancer and breast cancers. The therapeutic candidate is an antibody drug conjugate (ADC) and acts by targeting cells expressing folate receptor alpha (FRa). It is being developed based on ADC platform technology. It is administered through intravenous route.
Bio-Thera Solutions overview
Bio-Thera Solutions (Bio-Thera) is a clinical-stage biopharmaceutical company that carries out the research and development and production of innovative drugs and biosimilars. The company’s pipeline products include humanized monoclonal antibodies and peptide drugs such as BAT8001, BAT8003, BAT1306, BAT2094, and BAT4306F. It also offers BAT1406, an adalimumab biosimilar; BAT1706, a bevacizumab biosimilar; BAT1806, a tocilizumab biosimilar; and BAT2506. The company develops its products and therapies for the treatment of indications such as cancer, autoimmune diseases, cardiovascular diseases, arthritis, Crohn’s disease, psoriasis, polyarticular juvenile idiopathic arthritis (PJIA), and systemic juvenile idiopathic arthritis (SJIA). Bio-Thera is headquartered in Guangzhou, Guangdong, China.
For a complete picture of BAT-8006’s drug-specific PTSR and LoA scores, buy the report here.